Table 3– Characteristics of the four clusters of the Soonchunhyang University Asthma Genome Research Centre (SCH) patients
Cluster A′Cluster B′Cluster C′Cluster D′p-value
Subjects n217479585562
Age at onset years51.9±12.540.0±15.621.0±9.949.4±10.6<0.001
Time between symptom onset and start of treatment years6.19±8.288.62±11.1110.54±13.024.00±4.57<0.001
Body mass index kg·m−224.88±3.1924.05±3.5223.27±3.7125.11±3.17<0.001
Smoking pack-years37.2±16.04.5±7.22.7±6.03.2±7.2<0.001
Post-BD FEV1 % pred66.75±17.1854.25±13.3488.56±12.7197.70±13.92<0.001
Post-BD FEV1/FVC % pred64.81±11.5161.97±13.3380.05±10.0777.83±8.10<0.001
PC20 mg·mL−14.53±6.835.06±8.235.42±7.877.21±8.71<0.001
Blood eosinophils %5.41±4.585.87±5.504.91±4.415.30±5.360.024
Blood eosinophil count cells·mm−3411.4±367.4459.3±465.6355.2±387.0369.9±545.60.002
Log blood eosinophil count2.47±0.4332.49±0.482.39±0.412.39±0.42<0.001
Serum total IgE log IU·L−12.45±0.632.16±0.692.18±0.672.03±0.62<0.001
  • Data are presented as % or mean±sd, unless otherwise stated. Comparison between study groups is based on one-way ANOVA for continuous variables and a Chi-squared test for proportions. BD: bronchodilator; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; PC20: provocative concentration causing a 20% fall in FEV1.